
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 51, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 15 and 16 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 51, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 15 and 16 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
175 Pages
- Introduction
- Global Markets Direct Report Coverage
- Zika Virus Infections – Overview
- Zika Virus Infections – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Zika Virus Infections – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Zika Virus Infections – Companies Involved in Therapeutics Development
- Acer Therapeutics Inc
- Activirosomes Ltd
- Acuitas Therapeutics Inc
- Altimmune Inc
- Ascendo Biotechnology Inc
- Autonomous Therapeutics Inc
- Bharat Biotech Ltd
- BioCryst Pharmaceuticals Inc
- BioNet-Asia Co Ltd
- Biotron Ltd
- BravoVax Co Ltd
- Bugworks Research Inc
- CanSino Biologics Inc
- Cidara Therapeutics Inc
- Ciloa
- Cocrystal Pharma Inc
- Codagenix Inc
- Emergent BioSolutions Inc
- Emergex Vaccines Holding Ltd
- Enesi Pharma Ltd
- Ennaid Therapeutics LLC
- Enyo Pharma SA
- Eurocine Vaccines AB
- Excivion Ltd
- Expres2ion Biotechnologies ApS
- GeneOne Life Science Inc
- GeoVax Labs Inc
- GigaGen Inc
- Greffex Inc
- Hawaii Biotech Inc
- Hercules Pharmaceuticals BV
- IDBiologics Inc
- ImmunityBio Inc
- Imutex Ltd
- IMV Inc
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- iosBio Pharma Ltd
- Island Pharmaceuticals Ltd
- Johnson & Johnson
- Kamada Pharmaceuticals
- KM Biologics Co Ltd
- L2 Diagnostics LLC
- Mabloc LLC
- Macrophage Therapeutics Inc
- Medigen Inc
- Meletios Therapeutics SAS
- Merck & Co Inc
- Microbiotix Inc
- Moderna Inc
- Moleculin Biotech Inc
- NanoViricides Inc
- NightHawk Biosciences Inc
- Novalex Therapeutics Inc
- Ostrich Pharma USA Inc
- Palisades Therapeutics
- Plex Pharmaceuticals Inc
- Precision Virologics Inc
- ProtInhi BV
- Replikins Ltd
- ReVacc Biotech
- Riboscience LLC
- Sanofi
- Sementis Ltd
- Shanghai Junshi Bioscience Co Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- TenGen Biomedical Co
- Theravectys SA
- Tiba Biotech LLC
- Touchlight Genetics Ltd
- TrippBio Inc
- Tychan Pte Ltd
- Uvax Bio LLC
- VBI Vaccines Inc
- VenatoRx Pharmaceuticals Inc
- Vir Biotechnology Inc
- Virocovax
- Xenothera SAS
- Zika Virus Infections – Drug Profiles
- (chikungunya + Zika) (bivalent) vaccine – Drug Profile
- (dengue + zika) (pentavalent) vaccine – Drug Profile
- AC-10 – Drug Profile
- AGS-v – Drug Profile
- AGS-v PLUS – Drug Profile
- Antibodies for Viral Infections – Drug Profile
- Antibodies to Inhibit Envelope Protein for Dengue Fever and Zika Virus Infection – Drug Profile
- Antibody for Zika Virus Infections – Drug Profile
- Antiviral Therapies – Drug Profile
- BBV-121 – Drug Profile
- Biologics for Zika Virus Infections – Drug Profile
- CDX-ZIKV – Drug Profile
- CIL-15002 – Drug Profile
- CSB-013 – Drug Profile
- dengue + Zika virus vaccine – Drug Profile
- dengue-Zika (bivalent) vaccine – Drug Profile
- Drugs for Viral Infections – Drug Profile
- DWKM-1 – Drug Profile
- emetine hydrochloride – Drug Profile
- emricasan – Drug Profile
- EMX-001 – Drug Profile
- ETxR-12 – Drug Profile
- FIT-1 – Drug Profile
- Flavivirus Infections (Zika West Nile and Dengue Virus) – Drug Profile
- galidesivir – Drug Profile
- Gene Therapy for Zika Virus Infections – Drug Profile
- GEOZM-02 – Drug Profile
- GLS-5700 – Drug Profile
- HP-163 – Drug Profile
- infectious disease vaccine – Drug Profile
- INOA-002 – Drug Profile
- ISLA-101 – Drug Profile
- JNJ-66684657 – Drug Profile
- JT-109 – Drug Profile
- KD-406 – Drug Profile
- MLT-201 – Drug Profile
- MLT-301 – Drug Profile
- Monoclonal Antibody Conjugate for Dengue Fever and Zika Virus Infections – Drug Profile
- MR-766 – Drug Profile
- mRNA-1893 – Drug Profile
- MT-2002 – Drug Profile
- MTX-113 – Drug Profile
- MV-ZIKA – Drug Profile
- niclosamide – Drug Profile
- Pan Flavivirus T-cell Vaccine – Drug Profile
- Polysaccharides for Viral Infections – Drug Profile
- PV-ZIKV – Drug Profile
- RBS-1069 – Drug Profile
- REVC-150 – Drug Profile
- SCV-1002 – Drug Profile
- Small Molecule for Dengue Fever and Zika Virus Infections – Drug Profile
- Small Molecules for Dengue Fever and Zika Virus Infection – Drug Profile
- Small Molecules for Ebola and Zika Viral Infections – Drug Profile
- Small Molecules for Infectious Disease – Drug Profile
- Small Molecules for Viral Infections – Drug Profile
- Small Molecules for Zika Virus Infection – Drug Profile
- Small Molecules for Zika Virus Infections – Drug Profile
- Small Molecules to Antagonize Glucocorticoid Receptor for Viral Infections – Drug Profile
- Small Molecules to Inhibit NS2B and NS3 for Zika Virus Infections – Drug Profile
- Small Molecules to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections – Drug Profile
- Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections – Drug Profile
- sodium polystyrene sulfonate – Drug Profile
- SW-456 – Drug Profile
- Synthetic Peptide for Zika Virus Infection – Drug Profile
- TAK-426 – Drug Profile
- TD-214 – Drug Profile
- tyzivumab – Drug Profile
- Vaccine for Zika virus Infections and Glioblastoma – Drug Profile
- VBI-2501 – Drug Profile
- VIROX-1 – Drug Profile
- VRC-5283 – Drug Profile
- VRC-5288 – Drug Profile
- VSRD-ZIKV – Drug Profile
- WP-1096 – Drug Profile
- WP-1097 – Drug Profile
- XAV-3 – Drug Profile
- Z-004 – Drug Profile
- Zika (virus like particle) vaccine – Drug Profile
- Zika Antibody – Drug Profile
- Zika vaccine – Drug Profile
- Zika virus (monovalent) vaccine – Drug Profile
- Zika virus (virus like particle) vaccine – Drug Profile
- Zika virus 2 vaccine – Drug Profile
- Zika virus vaccine – Drug Profile
- Zika virus vaccine 1 – Drug Profile
- Zika virus vaccine 2 – Drug Profile
- Zika-HX – Drug Profile
- ZIKV-117 – Drug Profile
- ZIKV-rEfl – Drug Profile
- ZK-2B10 – Drug Profile
- Zika Virus Infections – Dormant Projects
- Zika Virus Infections – Discontinued Products
- Zika Virus Infections – Product Development Milestones
- Featured News & Press Releases
- Jan 26, 2021: Newly discovered molecule disrupts virus infections through protein quality control pathways
- Dec 02, 2020: Eurocine Vaccines has signed evaluation agreement to evaluate Endocine in the veterinary field
- Aug 20, 2020: Hercules AhR inhibitor HP163 blocks viral replication in Zika infection and potentially in Covid-19
- Jul 14, 2020: ExpreS2ion’s platform to be used in a novel Zika vaccine candidate
- Jul 13, 2020: CPI partners with Excivion to optimise and scale up production of safe and effective Zika vaccine
- Jun 15, 2020: Open Orphan : Positive phase I study results published in The Lancet
- Jun 10, 2020: Galidesivir stops Zika viral replication in primate model
- Apr 14, 2020: Moderna highlights opportunity of mRNA vaccines at its first vaccines day
- Mar 31, 2020: Eurocine Vaccines confirms adjuvant effect of Endocine with Zikavirus Vaccine Candidate
- Mar 11, 2020: Kamada provides update on Zika IgG product
- Feb 04, 2020: Plex Pharmaceuticals awarded $600,000 Phase I NIH SBIR grant to develop broad-spectrum antivirals to treat flavivirus infections
- Oct 02, 2019: Moderna to Present preclinical trial data of mRNA-1893 at IDWeek 2019
- Oct 01, 2019: Themis Bioscience and ZIKAVAX Consortium announce initiation of phase 1 Zika Vaccine Trial
- Sep 30, 2019: Vaccine against mosquito-borne diseases
- Aug 19, 2019: Moderna receives FDA fast track designation for Zika vaccine mRNA-1893
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Zika Virus Infections, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022
- Table 9: Products under Development by Companies, 2022 (Contd..1)
- Table 10: Products under Development by Companies, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022 (Contd..3)
- Table 12: Products under Development by Companies, 2022 (Contd..4)
- Table 13: Products under Development by Universities/Institutes, 2022
- Table 14: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 15: Number of Products by Stage and Target, 2022
- Table 16: Number of Products by Stage and Mechanism of Action, 2022
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Zika Virus Infections – Pipeline by Acer Therapeutics Inc, 2022
- Table 20: Zika Virus Infections – Pipeline by Activirosomes Ltd, 2022
- Table 21: Zika Virus Infections – Pipeline by Acuitas Therapeutics Inc, 2022
- Table 22: Zika Virus Infections – Pipeline by Altimmune Inc, 2022
- Table 23: Zika Virus Infections – Pipeline by Ascendo Biotechnology Inc, 2022
- Table 24: Zika Virus Infections – Pipeline by Autonomous Therapeutics Inc, 2022
- Table 25: Zika Virus Infections – Pipeline by Bharat Biotech Ltd, 2022
- Table 26: Zika Virus Infections – Pipeline by BioCryst Pharmaceuticals Inc, 2022
- Table 27: Zika Virus Infections – Pipeline by BioNet-Asia Co Ltd, 2022
- Table 28: Zika Virus Infections – Pipeline by Biotron Ltd, 2022
- Table 29: Zika Virus Infections – Pipeline by BravoVax Co Ltd, 2022
- Table 30: Zika Virus Infections – Pipeline by Bugworks Research Inc, 2022
- Table 31: Zika Virus Infections – Pipeline by CanSino Biologics Inc, 2022
- Table 32: Zika Virus Infections – Pipeline by Cidara Therapeutics Inc, 2022
- Table 33: Zika Virus Infections – Pipeline by Ciloa, 2022
- Table 34: Zika Virus Infections – Pipeline by Cocrystal Pharma Inc, 2022
- Table 35: Zika Virus Infections – Pipeline by Codagenix Inc, 2022
- Table 36: Zika Virus Infections – Pipeline by Emergent BioSolutions Inc, 2022
- Table 37: Zika Virus Infections – Pipeline by Emergex Vaccines Holding Ltd, 2022
- Table 38: Zika Virus Infections – Pipeline by Enesi Pharma Ltd, 2022
- Table 39: Zika Virus Infections – Pipeline by Ennaid Therapeutics LLC, 2022
- Table 40: Zika Virus Infections – Pipeline by Enyo Pharma SA, 2022
- Table 41: Zika Virus Infections – Pipeline by Eurocine Vaccines AB, 2022
- Table 42: Zika Virus Infections – Pipeline by Excivion Ltd, 2022
- Table 43: Zika Virus Infections – Pipeline by Expres2ion Biotechnologies ApS, 2022
- Table 44: Zika Virus Infections – Pipeline by GeneOne Life Science Inc, 2022
- Table 45: Zika Virus Infections – Pipeline by GeoVax Labs Inc, 2022
- Table 46: Zika Virus Infections – Pipeline by GigaGen Inc, 2022
- Table 47: Zika Virus Infections – Pipeline by Greffex Inc, 2022
- Table 48: Zika Virus Infections – Pipeline by Hawaii Biotech Inc, 2022
- Table 49: Zika Virus Infections – Pipeline by Hercules Pharmaceuticals BV, 2022
- Table 50: Zika Virus Infections – Pipeline by IDBiologics Inc, 2022
- Table 51: Zika Virus Infections – Pipeline by ImmunityBio Inc, 2022
- Table 52: Zika Virus Infections – Pipeline by Imutex Ltd, 2022
- Table 53: Zika Virus Infections – Pipeline by IMV Inc, 2022
- Table 54: Zika Virus Infections – Pipeline by Indian Immunologicals Ltd, 2022
- Table 55: Zika Virus Infections – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 56: Zika Virus Infections – Pipeline by iosBio Pharma Ltd, 2022
- Table 57: Zika Virus Infections – Pipeline by Island Pharmaceuticals Ltd, 2022
- Table 58: Zika Virus Infections – Pipeline by Johnson & Johnson, 2022
- Table 59: Zika Virus Infections – Pipeline by Kamada Pharmaceuticals, 2022
- Table 60: Zika Virus Infections – Pipeline by KM Biologics Co Ltd, 2022
- Table 61: Zika Virus Infections – Pipeline by L2 Diagnostics LLC, 2022
- Table 62: Zika Virus Infections – Pipeline by Mabloc LLC, 2022
- Table 63: Zika Virus Infections – Pipeline by Macrophage Therapeutics Inc, 2022
- Table 64: Zika Virus Infections – Pipeline by Medigen Inc, 2022
- Table 65: Zika Virus Infections – Pipeline by Meletios Therapeutics SAS, 2022
- Table 66: Zika Virus Infections – Pipeline by Merck & Co Inc, 2022
- Table 67: Zika Virus Infections – Pipeline by Microbiotix Inc, 2022
- Table 68: Zika Virus Infections – Pipeline by Moderna Inc, 2022
- Table 69: Zika Virus Infections – Pipeline by Moleculin Biotech Inc, 2022
- Table 70: Zika Virus Infections – Pipeline by NanoViricides Inc, 2022
- Table 71: Zika Virus Infections – Pipeline by NightHawk Biosciences Inc, 2022
- Table 72: Zika Virus Infections – Pipeline by Novalex Therapeutics Inc, 2022
- Table 73: Zika Virus Infections – Pipeline by Ostrich Pharma USA Inc, 2022
- Table 74: Zika Virus Infections – Pipeline by Palisades Therapeutics, 2022
- Table 75: Zika Virus Infections – Pipeline by Plex Pharmaceuticals Inc, 2022
- Table 76: Zika Virus Infections – Pipeline by Precision Virologics Inc, 2022
- Table 77: Zika Virus Infections – Pipeline by ProtInhi BV, 2022
- Table 78: Zika Virus Infections – Pipeline by Replikins Ltd, 2022
- Table 79: Zika Virus Infections – Pipeline by ReVacc Biotech, 2022
- Table 80: Zika Virus Infections – Pipeline by Riboscience LLC, 2022
- Table 81: Zika Virus Infections – Pipeline by Sanofi, 2022
- Table 82: Zika Virus Infections – Pipeline by Sementis Ltd, 2022
- Table 83: Zika Virus Infections – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 84: Zika Virus Infections – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 85: Zika Virus Infections – Pipeline by TechnoVax Inc, 2022
- Table 86: Zika Virus Infections – Pipeline by TenGen Biomedical Co, 2022
- Table 87: Zika Virus Infections – Pipeline by Theravectys SA, 2022
- Table 88: Zika Virus Infections – Pipeline by Tiba Biotech LLC, 2022
- Table 89: Zika Virus Infections – Pipeline by Touchlight Genetics Ltd, 2022
- Table 90: Zika Virus Infections – Pipeline by TrippBio Inc, 2022
- Table 91: Zika Virus Infections – Pipeline by Tychan Pte Ltd, 2022
- Table 92: Zika Virus Infections – Pipeline by Uvax Bio LLC, 2022
- Table 93: Zika Virus Infections – Pipeline by VBI Vaccines Inc, 2022
- Table 94: Zika Virus Infections – Pipeline by VenatoRx Pharmaceuticals Inc, 2022
- Table 95: Zika Virus Infections – Pipeline by Vir Biotechnology Inc, 2022
- Table 96: Zika Virus Infections – Pipeline by Virocovax, 2022
- Table 97: Zika Virus Infections – Pipeline by Xenothera SAS, 2022
- Table 98: Zika Virus Infections – Dormant Projects, 2022
- Table 99: Zika Virus Infections – Dormant Projects, 2022 (Contd..1)
- Table 100: Zika Virus Infections – Dormant Projects, 2022 (Contd..2)
- Table 101: Zika Virus Infections – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Zika Virus Infections, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.